Spinal subarachnoid injection of somatostatin causes neurological deficits and neuronal injury in rats

The tetradecapeptide somatostatin produced dose-related neurological deficits following subarachnoid injection in the lumbar spinal cords of rats. Lower pharmacological doses (1.6 and 3.1 nmol, i.t.) of somatostatin caused only transient deficits, while higher doses (6.2-25 nmol, i.t.) caused persistent deficits characterized by motor and sensory impairments in hindlimbs and tail, hindlimb edema, priapism, bladder atony with infarction, and urinary incontinence. Pretreatment with 0.3 nmol of the somatostatin receptor antagonist cyclo[7-aminoheptanoyl-Phe-D-Trp-Lys-Thr(Bzl)] blocked the hindlimb paralytic effects of 3.1 and 6.2 nmol of somatostatin, and significantly improved neurological recovery injection of 12.5 nmol of somatostatin. Higher doses of the antagonist produced hindlimb paralysis by itself. Neuroanatomical evaluations revealed extensive cell loss and necrosis in the lumbosacral spinal cords of rats paralyzed by 25 nmol of somatostatin. Collectively, these results suggest that through interactions with a receptor, somatostatin destroys neurons involved in diverse spinal cord functions.

Ventral hernia following abdominal aortic reconstruction

An unexpectedly high frequency of ventral incisional hernia in our aortic reconstruction patients prompted us to review a recent three year period. Of 76 aortic reconstruction patients, 66 were evaluable for at least one year following their aortic procedure. In these 66 patients, ventral incisional hernias occurred in 14 (21.2%). Of statistical significance (P less than .01) was that ten of the 14 hernias occurred in the 27 aneurysm patients (37%) and four occurred in the 39 occlusive disease patients (10%). Though a comparison group of aneurysm patients is not available in the literature, the incidence of hernia in our occlusive disease population is consistent with the literature experience when careful long-term follow-up is employed. These observations may represent another manifestation of previously reported differences between aortic aneurysm and occlusive atherosclerotic populations.

Neurologic deficits and neuronal injury in rats resulting from nonopioid actions of the delta opioid receptor antagonist ICI 174864

The delta opioid receptor antagonist ICI 174864 produces postural abnormalities and barrel rolling after i.c.v. injection and hindlimb and tail flaccidity after spinal subarachnoid injection in rats. These effects appear to result from nonopioid characteristics of ICI 174864 because they are neither shared nor blocked by other opioid antagonists (naloxone, ICI 154129 and WIN 44,441-3) and are produced by two compounds (ICI 174644 and ICI 178173) that are structurally related to ICI 174864 but lack its delta antagonist properties. Barrel rolling and hindlimb paralysis are also produced by dynorphin A-related peptides; however, rats failed to demonstrate tolerance or cross-tolerance to the hindlimb paralytic actions of ICI 174864 or dynorphin A (1-13) after 7 days of continuous spinal intrathecal infusion of either of these compounds. Whereas hindlimb responses to low doses of ICI 174864 (1.6-6.2 nmol intrathecally) were usually transient, higher doses (6.2-25 nmol intrathecally) produced persistent hindlimb motor dysfunction, altered nociception, priapism, hindlimb edema, bladder infarction and atony and urinary incontinence. Neuronal and axonal changes in the lumbosacral spinal cords of rats with persistent and transient neurologic deficits provided direct evidence of the neuropathologic actions of ICI 174864 (3.1 and 6.2 nmol) and ICI 174644 (25 nmol). These results indicate that 1) use of ICI 174864 as a selective delta opioid receptor antagonist is potentially compromised by its nonopioid neuropathologic actions and 2) ICI 174864 and dynorphin A-related peptides are unique among opioid agonists and antagonists in sharing barrel rolling and hindlimb paralytic effects. A similar mechanism of action may underlie the shared nonopioid actions of these peptides.

Intrathecal dynorphin A1-13 and dynorphin A3-13 reduce rat spinal cord blood flow by non-opioid mechanisms

Radiolabeled microspheres were used to examine the effects of paralytic intrathecal doses of dynorphin A (Dyn A1-13) and Dyn A3-13 on rat brain and spinal cord blood flows and cardiac output. Dyn A1-13 produced significant dose-related reductions in blood flow to lumbosacral and thoracic spinal cord without altering cardiac output and blood flow to brain and cervical spinal cord. Naloxone failed to block these effects. Dyn A3-13, which lacks opioid activity, also significantly reduced blood flow in lumbosacral spinal cord. Thus, the paralytic effects of Dyn A in the rat may involve reductions in spinal cord resulting from non-opioid actions of Dyn A.

Cardiovascular effects of dynorphin A (1-13) in conscious rats and its modulation of morphine bradycardia over time

The short-term cardiovascular effects of dynorphin A (1-13), as well as its effects upon morphine bradycardia were investigated. In unanesthetized, unrestrained rats, intracerebroventricular (ICV) dynorphin A (1-13) injections (10-20 micrograms) produced a dose-related pressor effect, whereas intravenous (IV) dynorphin A (1-13) (1.0 mg/kg) produced a depressor effect; these responses persisted less than five min. Heart rate was not significantly altered by these doses or routes of administration. Dynorphin A (1-13) also produced behavioral effects in the unanesthetized animals, such as wet dog shakes in response to IV administration and wet dog shakes accompanied by barrel rolling in response to ICV administration. To evaluate the effects of dynorphin A (1-13) pretreatment on the bradycardic response to IV morphine, rats were pretreated with 10 micrograms dynorphin A (1-13) ICV four, six or eight hours prior to challenge with morphine sulfate (0.1 mg/kg IV). Four hour pretreatment with dynorphin A (1-13) (tested at 14:00 hr) resulted in a potention of morphine bradycardia, with six hours pretreatment (tested at 16:00 hr) no effect was observed, and eight hours following dynorphin A (1-13) pretreatment (tested at 18:00 hr) morphine bradycardia was attenuated. Additionally, the bradycardic response to IV morphine alone became more exaggerated as rats approached their nocturnal activity cycle. These data further establish that dynorphin A (1-13) exerts a potent, long lasting modulatory effect on morphine bradycardia and emphasize the importance of circadian variables in altering the magnitude of cardiovascular responses to opioid agonists.

NGF effects on developing forebrain cholinergic neurons are regionally specific

Nerve growth factor (NGF) has been shown to have an effect on neurons in the central nervous system (CNS). A number of observations suggest that NGF acts as a trophic factor for cholinergic neurons of the basal forebrain and the caudate-putamen. We sought to further characterize the CNS actions of NGF by examining its effect on choline acetyltransferase (ChAT) activity in the cell bodies and fibers of developing neurons of the septum and caudate-putamen. ChAT activity was increased after even a single NGF injection. Interestingly, the magnitude of the effect of multiple NGF injections suggested that repeated treatments may augment NGF actions on these neurons. The time-course of the response to NGF was followed after a single injection on postnatal day (PD) 2. NGF treatment produced long-lasting increases in ChAT activity in septum, hippocampus and caudate-putamen. The response in cell body regions (septum, caudate-putamen) was characterized by an initial lag period of approximately 24 hr, a rapid rise to maximum values, a plateau phase and a return to baseline. The response in hippocampus was delayed by 48 hr relative to that in septum, indicating that NGF actions on ChAT were first registered in septal cell bodies. Finally, developmental events were shown to have a regionally specific influence on the response of neurons to NGF. For though the septal response to a single NGF injection was undiminished well into the third postnatal week, little or no response was detected in caudate-putamen at that time. In highlighting the potency and regional specificity of NGF effects, these observations provide additional, support for the hypothesis that NGF is a trophic factor for CNS cholinergic neurons.

Three-dimensional distribution of collateral blood flow within the anatomic area at risk after circumflex coronary artery occlusion in dogs

It is generally accepted that occlusion of a major coronary artery in the dog results in a transmural gradient of collateral blood flow, with the subepicardial region receiving the greatest perfusion. The lateral and base to apex distribution of collateral blood flow and of metabolic and functional consequences of ischemia have been more difficult to define. One reason for such difficulties has been the failure to define the anatomic boundaries of the ischemic vascular bed so that uncontaminated samples of ischemic and non-ischemic tissue could be selected for study. In the present study, the three dimensional distribution of myocardial blood flow during occlusion of the circumflex artery was mapped in seven dogs. At the end of the study, the boundaries of previously ischemic and non-ischemic regions were identified by simultaneous coronary perfusion with red and blue dyes. Left ventricular slices were separated into ischemic and non-ischemic vascular beds based on the dye boundaries, with 1-2 mm of tissue trimmed from this interface to eliminate visually apparent admixture. The ischemic vascular bed of each cross sectional slice then was cut into five transmural wedges, each 3-5 mm wide; each wedge was further subdivided into subendocardial, middle, and subepicardial thirds. The results of blood flow measurements in these samples indicate that the dye injection technique identifies a real interface with a sharp lateral transition in blood flow between ischemic and non-ischemic vascular beds. Within the ischemic vascular bed, there is a transmural gradient of collateral blood flow, but within a given mural layer, there is no consistent gradient from the center to lateral edge or from base to apex of the ischemic region. Thus, in studies designed to characterize the properties of myocardium on either side of the ischemic/non-ischemic interface, reasonable resolution can be achieved by coronary dye infusions to permit visual identification of this interface. On the other hand, in studies in which collateral blood flow is measured as a baseline predictor of infarct size, measurements can be made in a central ischemic block which will be representative of most or all of the ischemic region. Borderzone samples can be excluded to avoid contamination of ischemic samples with non-ischemic tissue.

Intracerebroventricular administration of superFIT and its enantiomer to rats: evidence for in vivo acylation of [3H]DADL binding sites

SuperFIT is an high affinity acylating ligand derived from fentanyl. Previous studies suggested that a selective acylation of delta receptors (J. Med. Chem. 29:1087-1093, 1986) resulted from exposure of membranes to this and structurally related compounds. We report in this preliminary study that intracerebroventricular administration of either superFIT or its enantiomer 18 to 24 hours prior to sacrifice decreased the subsequent binding of [3H]DADL to both its higher and lower affinity binding sites.

Effects of adrenalectomy and hypophysectomy on postictal seizure protection

Endogenous opioid systems activated by seizures appear to contribute to the postictal inhibition of subsequent seizure activity. In consideration of the possible postictal anticonvulsant actions of endogenous opioids of peripheral origin, we examined whether intact adrenal or pituitary sources of these opioids are necessary for the progressive decline in convulsion intensity and duration normally recorded during a series of 6 intermittent maximal electroshocks (MES). Adrenalectomy did not alter the progressive seizure protection associated with repeated MES. Hypophysectomy, in contrast, increased convulsion duration and abolished progressive reductions in convulsion severity. These data indicate that: adrenal secretions do not substantially contribute to postictal protective mechanisms, and endogenous opioids of pituitary origin may be involved in postictal protective mechanisms.

Selective surgical management of perforated duodenal ulcer

In an effort to clarify the preoperative indications and factors predisposing to an increased operative morbidity for "definitive" ulcer procedures, the medical records of 114 patients with perforated duodenal ulcers were reviewed. One hundred nine patients underwent operation, with 55 patients treated with ulcer closure (Group 1) and 54 underwent a "definitive" operation (Group 2). Thirty-two complications developed in 27 patients (25%), with major infectious complications occurring in 9 per cent and 7.5 percent in the simple ulcer closure and definitive surgery groups, respectively. This study demonstrates that preoperative shock, operation delayed greater than 48 hours, and patient age greater than 60 years were significant factors increasing morbidity. The importance of peritoneal soilage and positive cultures are unreliable in predicting subsequent clinical infection and do not contraindicate definitive surgical management.

Endogenous opioids in spinal cord injury: a critical evaluation

Based upon evidence that opioid antagonists improve neurological outcome following either traumatic or ischemic spinal cord injury, endogenous opioids have been implicated in the pathophysiology of these disorders. Naloxone improved both spinal cord perfusion and neurological function following traumatic spinal cord injury in cats, and was subsequently observed to improve neurological outcome following ischemic spinal cord injury in rabbits. Using several opioid antagonists with varied selectivities for different types of opioid receptors, it was suggested that kappa opioid receptors are involved in both these models of spinal cord injury. In addition, spinal cord trauma in rats is associated with increased concentrations of the endogenous kappa agonist dynorphin A, and increased kappa opioid receptor binding capacity localized to the injury site. Furthermore, dynorphin A induces hindlimb and tail flaccidity following intrathecal injection in rats. Thus, the pathophysiological effects of endogenous opioids in spinal cord injury have been proposed to involve dynorphin A interactions with kappa opioid receptors. However, disparities between the actions of intrathecally injected dynorphin A in rats and the presumed actions of endogenous dynorphin A in cat and rabbit spinal cord injury have been revealed in recent experiments. Paralysis resulting from intrathecal dynorphin A is not altered by opioid receptor antagonists or TRH, produced by non-opioid dynorphin A fragments but not by other selective kappa opioid agonists, and associated with non-opioid mediated reductions in spinal cord blood flow. Furthermore, despite reports of endogenous opioid changes following rat spinal cord trauma, in contrast to cats and rabbits, naloxone failed to improve neurological outcome following traumatic rat spinal cord injury. Thus, the specific endogenous opioids and opioid receptor types involved in spinal cord injury remain to be resolved, and do not appear to be universal among different models of spinal cord injury in different species. Additionally, dynorphin A may participate in spinal cord injury mechanisms in the rat through non-opioid actions.

An improved method for the analysis of sister-chromatid exchange in vivo

A single injection method of halogenated nucleosides for analysis in vivo of SCE is reported. Halogenated nucleosides were suspended in plant oils, such as peanut oil, and injected into mice subcutaneously. When the dosage of halogenated nucleosides reached 500 mg/kg, satisfactory differential sister chromatid staining of bone marrow cells was obtained. This technique was simple, neither special equipment nor surgical procedure was needed, and the dosage of halogenated nucleosides was relatively low.

Endogenous anticonvulsant substance in rat cerebrospinal fluid after a generalized seizure

Cerebrospinal fluid taken from rats subjected to electroshock-induced seizures and injected into the cerebral ventricles of rats that had not been shocked increased the seizure threshold of the recipients. The anticonvulsant activity of the donor cerebrospinal fluid was antagonized by opioid antagonists and enhanced by peptidase inhibitors. These results suggest the existence of an endogenous anticonvulsant substance in rat cerebrospinal fluid, possibly opioid in nature, which is activated as a consequence of a seizure and which may play a critical role in postseizure inhibition.

Endogenous opioid systems: physiological role in the self-limitation of seizures

Immediately following a seizure, the severity of subsequent seizures is significantly reduced. The involvement of endogenous opioid systems as a physiological regulator of this postseizure inhibition was studied in rats using repeated maximal electroshock (MES) seizures. Both the opiate antagonist (-)-naloxone and morphine tolerance abolished the progressive seizure protection associated with repeated MES. We propose that endogenous opioids, activated by a prior seizure, provide a central homeostatic inhibitory mechanism which may be responsible for the initiation of a postictal refractory state in the epileptic.

Blood-brain barrier: endogenous modulation by adrenal-cortical function

The blood-brain barrier restricts the passage of molecules from the blood to the brain. The permeability of the barrier to iodine-125-labeled bovine serum albumin was examined in rats that had undergone adrenalectomy, adrenal demedullation, and corticosterone replacement. Adrenalectomy, but not adrenal demedullation, increased the permeability of brain tissue to the isotopically labeled macromolecule; corticosterone replacement reversed this effect. These results indicate that the blood-brain barrier may be hormonally regulated; that is, the pituitary-adrenal axis may physiologically modulate the permeability of the brain microvasculature to macromolecules.

Opioids and neuropeptides: mechanisms in circulatory shock

Endogenous opioid systems are activated in stressful situations such as circulatory shock. The opiate antagonist naloxone improves cardiovascular function in several models of shock caused by endotoxemia, hypovolemia, anaphylaxis, and spinal trauma. The ergotropic neuropeptide, thyrotropin-releasing hormone, in supraphysiological doses, also improves cardiovascular function in these shock models, but this effect does not result from action at the opiate receptor. For both these agents a central nervous system (CNS) site of action has been partially characterized. A variety of neuropeptides, including the opioids, seem capable of modulating autonomic function through their CNS actions. In addition, they may play a role in peripheral integration and transmission of autonomic nervous activity by actions at the ganglia and/or at nerve endings. Some neuropeptides also have direct autacoid effects on cells, including those of the microvasculature. This raises new questions concerning possible peripheral functions of neuropeptides during circulatory shock, and the nature of their interactions with other potential shock mediators such as monokines and arachidonic acid derivatives.

Results of revascularization and amputation in severe lower extremity ischemia: a five-year clinical experience

Aggressive revascularization of the ischemic lower extremity in atherosclerotic occlusive disease by femoropopliteal (FP) and femorotibial (FT) bypass or profundaplasty (P), as indicated, has been advocated by some authors for all patients. Others have recommended primary amputation, particularly for tibial occlusive disease. To clarify this clinical dilemma, we reviewed the results of 547 procedures performed during the last 5 years: revascularization in 375 (69%) instances and below-knee amputation (BKA) in 172 (31%) cases. Bypass procedures were used in 246 cases: FP in 155 (64%) and FT in 91 (37%). Reversed autogenous saphenous vein (ASV) was used preferentially in 125 (51%) cases, whereas polytetrafluoroethylene (PTFE) was used in 121 (49%) cases. P was performed in 129 instances accompanied by inflow procedures in 92 (71%) of these cases. Cumulative limb salvage (LS) exceeded bypass patency in all categories and resulted in 2- and 5-year LS rates of 83% and 81% for FP with the use of ASV and 52% and 35% for PTFE. The LS rate for FT was 53% and 47%, respectively, for ASV and 20% and 15% for PTFE. Rest pain was successfully relieved by P in 99 cases (77%), whereas healing occurred in only 51% of cases with tissue loss. The perioperative mortality rate for revascularization was 3%; 42% of the group died during follow-up, death usually resulting from complications of atherosclerosis. Of the 172 BKAs, primary healing occurred in 80%, but the perioperative mortality rate was 13%. FP and FT bypasses are preferred procedures if ASV is available, whereas use of PTFE should be limited to FP bypasses only. Rest pain is relieved by P but tissue loss should prompt consideration for bypass. BKA should be considered in cases of severe tibial disease only in the absence of a suitable ASV, as the perioperative mortality rate is high and ultimate rehabilitation (64%) is limited.

Asymptomatic carotid disease

The advent of noninvasive screening tests has allowed the identification of an increasing number of patients with asymptomatic carotid stenoses. The management of these patients must be individualized, as the preferred method of therapy has not been established. Such a solution ultimately requires a prospective randomized trial to define the natural history of these lesions and to clearly establish if surgical therapy has a role. Currently, there is a Veterans Administration Cooperative Study underway which will attempt to fill the existing information gap. Specifically being examined is the relationship between subsequent cerebrovascular symptoms and the degree of stenosis, progression of stenosis, contralateral disease and non-carotid operation. This study will not be completed for five years, so that other, current guidelines must be sought. It is essential that any surgeon considering prophylactic carotid endarterectomy demonstrate combined morbidity and mortality figures of less than 3 per cent. The patients being considered must also be an acceptable cardiac risk, as myocardial infarction represents the most common postoperative complication. Until prospective data is available, with a detailed analysis of the degree of stenosis, presence of ulceration and ultimate clinical course, the surgeon undertaking prophylactic endarterectomy must carefully screen his patients and concentrate on groups at high risk. This is especially important as more data on the significant incidence (10 to 15 per cent) of carotid restenosis becomes available. The results of three studies (34, 36, 69) suggest that those patients with hemodynamically significant stenoses, identified noninvasively by OPG techniques, are at a greater risk for cerebral ischemic events than those patients without significant stenoses. In addition, an observed incidence of stroke of 17.5 per cent and an indicence of TIAs of 33 per cent in patients with disease progression demonstrated by OPG-K/CPA. The work of another researcher (71) suggests that patients with carotid stenoses can be observed until symptoms develop or until the stenosis progresses to greater than 80 per cent.(ABSTRACT TRUNCATED AT 400 WORDS)

ICI 174864, a putative delta opioid antagonist, reverses endotoxemic hypotension: pretreatment with dynorphin 1-13, A kappa agonist, blocks this action

The putative delta opioid receptor antagonist ICI 174864 (3 mg/kg, i.v.) significantly reversed endotoxic shock hypotension at a dose which lacked significant pressor actions in normotensive, non-endotoxemic rats. In contrast, dynorphin 1-13, when administered either before (0.1 or 1.0 mg/kg, i.v.) or following (1.0 mg/kg, i.v.) injection of endotoxin, failed to alter the course of ensuing circulatory shock. Additionally, pretreatment with dynorphin 1-13 prevented the subsequent reversal of endotoxemic hypotension by ICI 174864. It is concluded that: 1) delta opioid receptors mediate the endogenous opioid component of endotoxic shock hypotension; and 2) functional interactions occur between ligands for mu, delta, and kappa opioid receptor subtypes, which may predict potential interactions with a common macromolecular opioid receptor complex.

The assessment of skin blood flow in peripheral vascular disease by laser Doppler velocimetry

The helium-neon laser Doppler (LD) is designed to measure skin blood flow velocity (SBFV). Flow velocity and pulse wave amplitude are expressed in millivolts (mv) relative to a zero-flow reference. The authors have reviewed their initial experience in ten persons (20 limbs) without peripheral vascular disease (PVD, group I) and nine patients (12 limbs) with severe PVD (group II). The finger, palm, great toe, and forehead had a significantly (P less than 0.05) greater flow velocity than the plantar and dorsal foot, distal and proximal leg, thigh, chest, arm, and forearm. Baseline and hyperemic SBFV, measured at the great toe, were compared in groups I and II. In group I, the baseline SBFV (mv, mean +/- standard error of the mean (SEM] in the great toe was 197 +/- 38 compared with 67 +/- 12 in group-II patients (P less than 0.05). The pulse wave amplitude (mv, mean +/- SEM) was 77 +/- 14 in group I and 5.4 +/- 1.1 in group II (P less than 0.05). The time to maximal hyperemic response (seconds, mean +/- SEM) in group I was 18 +/- 1.5 compared with 150 +/- 14 in group II (P less than 0.05). LD is a sensitive indicator of changes in SBFV, allowing differentiation between normal persons and patients with PVD. The LD tracing in patients with PVD is characterized by a baseline SBFV that is significantly less than normal and also by the attenuation or absence of pulse waves. The diagnostic accuracy is enhanced by the use of reactive hyperemia.

Possible involvement of serotonergic neurotransmission in neurotensin but not morphine analgesia

The purpose of this study is to determine whether the antinociceptive properties of morphine and neurotensin (NT) are dependent upon central serotonergic neurotransmission. To this end, we studied the effects of morphine (10 mg/kg i.p.) and NT (30 micrograms i.c.v.) on the turnover of 5-hydroxytryptamine (5-HT) in 8 microdissected nuclei of adult rat brain: n. septalis lateralis (LS); n. tractus diagonalis (DB); n. amygdaloideus centralis (AG); posterior medial forebrain bundle (MFB); periaqueductal gray (PAG); n. raphe dorsalis (DR); n. centralis superior (NCS); and n. raphe magnus (RM). The systemic administration of morphine did not alter rates of 5-hydroxytryptophan (5-HTP) biosynthesis in any of the nuclei examined, although concentrations of serotonin were increased by 24% in the RM. In contrast, the central administration of neurotensin significantly decreased the rate of 5-HTP biosynthesis in the posterior MFB. The central administration of NT was accompanied by increased levels of serotonin in the DB, DR, and RM and by decreased serotonin levels in the MFB and PAG. In a complementary series of experiments, the effect of depletion of central 5-HT stores on the antinociceptive properties of both morphine and NT was determined. p-Chlorophenylalanine (PCPA, 325 mg/kg, i.p.) decreased whole brain 5-HT levels by 87%, but had no effect upon the increase in hot plate latencies induced by morphine. Conversely, although without significant antinociceptive properties of its own, PCPA markedly potentiated the antinociceptive effects of NT.(ABSTRACT TRUNCATED AT 250 WORDS)

Effects of castration and adrenalectomy on in vitro rates of tryptophan hydroxylation and levels of serotonin in microdissected brain nuclei of adult male rats

Rates of 5-hydroxytryptophan (5-HTP) synthesis and levels of serotonin (5-HT) were measured in microdissected brain nuclei following castration or adrenalectomy of adult male rats. Fourteen days following gonadectomy, 5-HTP synthesis decreased in the nucleus raphe dorsalis (DR) and nucleus centralis superior (NCS), while levels of 5-HT were unchanged in the 7 brain nuclei examined. Administration of testosterone to castrated rats not only did not reverse the castration-induced decrease in 5-HTP synthesis in the DR and NCS, but also decreased 5-HT synthesis in the nucleus amygdaloideus centralis (AGC) and the nucleus septalis lateralis (LS). Following administration of testosterone, 5-HT levels were unchanged. 10 days following bilateral adrenalectomy, 5-HTP synthesis increased in the NCS and the median eminence. Levels of 5-HT increased only in the median eminence. The increased 5-HTP synthesis and 5-HT levels following adrenalectomy were not reversed by corticosterone administration. In addition, these selective changes in 5-HT metabolism did not result from hormonal effects on the availability of tryptophan to the brain. We conclude that there are subsets of serotonergic neurons in rat central nervous system which respond uniquely to removal of the gonads and adrenals. Furthermore, the dissociation between serum and brain tryptophan concentrations and changes in rates of 5-HTP synthesis argue against tryptophan availability as being a primary determinant of 5-HT biosynthesis and for a direct endocrine central nervous system interaction with serotonergic neurons.

Regional differences in the response of serotonergic neurons in rat CNS to drugs

In vivo rates of 5-hydroxytryptophan accumulation (following administration of the decarboxylase inhibitor R04/4602/1) and levels of 5-HT in the nucleus raphe dorsalis (DR), nucleus centralis superior (NCS), nucleus septalis lateralis (LS), nucleus suprachiasmaticus (SCN), nucleus hypothalamicus anterior (AH), and nucleus amygdaloideus centralis (AG) were determined following administration of fluoxetine, 5-methoxy-N,N-dimethyltryptamine, methiothepin, L-tryptophan and reserpine. Fluoxetine and 5-methoxy-N,N-dimethyltryptamine inhibited 5-hydroxytryptophan synthesis in all nuclei, although inhibition of synthesis in the DR was resistant to fluoxetine. Methiothepin inhibited 5-HT synthesis in the DR, NCS, LS and AG, but not in the SCN or AH. L-Tryptophan greatly increased 5HT synthesis in all areas, but this increase was not uniform, being fourfold greater in the NCS than in the LS. Reserpine, while greatly depleting 5HT did not increase 5-hydroxytryptophan synthesis in any nucleus. In no region could changes in brain tryptophan account for the observed drug effects on serotonin metabolism. We conclude that not all CNS serotonergic structures respond to the same drug in a uniform manner.

A microassay for simultaneous measurement of in vivo rates of tryptophan hydroxylation and levels of serotonin in discrete brain nuclei

A sensitive procedure for simultaneous determination of in vivo rates of tryptophan hydroxylation and levels of serotonin (5-HT) in discrete rat brain nuclei is described. Rates of tryptophan hydroxylation are estimated by 5-hydroxytryptophan (5-HTP) accumulation following l-aromatic amino acid decarboxylase inhibition by R04-4602/1. 5-HTP is separated from 5-HT by liquid cation exchange after which both 5-HTP and 5-HT are measured by a sensitive radioenzymatic assay. Following decarboxylase inhibition, 5-HTP accumulates over 30 min in 6 brain nuclei examined, with negligible levels of 5-HTP being measured in the absence of decarboxylase inhibition. 5-HT levels do not change significantly up to 45 min after decarboxylase inhibition. Comparison of rates of tryptophan hydroxylation determined in 12 different microdissected rat brain areas reveals a greater rate of 5-HT biosynthetic activity in raphe nuclei containing 5-HT cell bodies than in nuclei containing 5-HT terminals. Pretreatment with para-chlorophenylalanine markedly reduces both 5-HTP accumulation and 5-HT levels in the nucleus raphe dorsalis. With this procedure quantities as little as 10 pg of both 5-HTP and 5-HT can be measured, allowing estimation of in vivo serotonin biosynthesis in microgram quantities of brain tissue.

Secondary reinforcement as a function of the interstimulus interval: a confutation

After bar training, 3 of 5 groups of 9 rats received runway discrimination training presenting a buzzer as the discriminative stimulus: I—in the start box; II—in the alley; III—as the goal box was entered. For Group IV the buzzer sounded after the reward was seized and Group V was not exposed to the buzzer. After Group I attained the criterion of discrimination, Ss were tested in the Skinner box with bar depression sounding the buzzer for .75 sec. Contrary to the hypothesis that all discriminative stimuli are secondary reinforcers (Keller & Schoenfeld, 1950), there was no evidence that the buzzer had acquired reward value.

Elicitation and reinforcement as separate stimulus functions

3 groups of 16 rats were trained to discriminate between two distinctive end boxes. Two groups discriminated between goal boxes while the third group discriminated between start boxes. These stimuli were then tested as secondary reinforcers in a T-maze. The groups trained to discriminate between goal boxes showed a statistically significant preference for the goal box previously associated with reinforcement. The third group showed no preference. It was concluded that discrimination training is not sufficient to establish an Sr without contiguity of stimulus and reward.

Resistance to extinction under variable conditions as a function of the intertrial interval

72 rats were given 8 acquisition trials under constant acquisition conditions and then extinguished under constant (C), variable (V) and interpolated rest (R) conditions. The V and R conditions did not differ significantly from one another but both differed significantly from the C condition. It was concluded that the rate of extinction is inhibited when extinction trials are widely distributed, regardless of whether the intertrial interval is filled or not.